Last reviewed · How we verify
NCT05004220
Effects of Plasmapheresis on Aging Biomarkers
trial testing Plasmapheresis in Aging in 41 participants. Completed in 10 February 2023.
16 August 2021
Quick facts
| Lead sponsor | Charles University, Czech Republic |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 41 |
| Start date | 6 April 2021 |
| Primary completion | 16 August 2021 |
| Estimated completion | 10 February 2023 |
| Sites | 1 location across Czechia |
Drugs / interventions tested
- Plasmapheresis — full drug profile →
Conditions studied
- Aging — all drugs for Aging →
- Plasmapheresis — all drugs for Plasmapheresis →
Sponsor
Charles University, Czech Republic
Who can join
Adults 40 to 60, any sex, with Aging or Plasmapheresis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of the study is to evaluate the effect of plasmapheresis (repeated plasma withdrawals) on selected health indicators (hematological, biochemical, immunological and indicators of biological age) of plasma donors.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Multi-Omics Analysis Reveals Biomarkers That Contribute to Biological Age Rejuvenation in Response to Single-Blinded Randomized Placebo-Controlled Therapeutic Plasma Exchange.
Fuentealba M, Kiprov D, Schneider K, Mu WC, et al · · 2025 · cited 10× · PMID 40424097 · DOI 10.1111/acel.70103 -
Human clinical trial of plasmapheresis effects on biomarkers of aging (efficacy and safety trial).
Borsky P, Holmannova D, Parova H, Horvath S, et al · · 2025 · cited 1× · PMID 40592961 · DOI 10.1038/s41598-025-05396-0
Verify or expand the search:
- PubMed search for NCT05004220
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Plasmapheresis
Trials testing the same drug.
- NCT07087860 — Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers · Phase 2 · recruiting
- NCT06597656 — A Gene Transfer Therapy to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Therape · Phase 1 · terminated
- NCT05562960 — Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP · NA · recruiting
- NCT05815615 — Plasmapheresis: a Multi-modal Approach · NA · completed
- NCT05179200 — The Effect of Plasma Donation Frequency on Donor Health · NA · completed
Other recruiting trials for Aging
Currently open trials in the same condition.
- NCT02831335 — Technical Development of Multi-Parametric Renocerebral MRI · recruiting
- NCT07099053 — Amyloid PET Imaging in the Baltimore Longitudinal Study of Aging · recruiting
- NCT07504068 — Effects of Physical Exercise and a Nutritional Supplement on Body Composition, Metabolic Function, and Overall Health in · NA · recruiting
- NCT07525453 — Effects of Three Different Exercise Programs on Dynamic Balance in Community-Dwelling Older Adults · NA · recruiting
- NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting
Other Charles University, Czech Republic trials
Trials by the same sponsor.
- NCT07475481 — Exercise-Based Strategies for Chronic Back Pain · NA · not yet recruiting
- NCT07468318 — Multimodal Therapy for Somatosensory Tinnitus · NA · not yet recruiting
- NCT07525154 — Development of a Certified Testing Procedure for Hip and Groin Injuries in Athletes · NA · not yet recruiting
- NCT07512570 — Feasibility and Preliminary Effects of a Structured Resistance Training Program in Children Aged 10-14 Years · NA · not yet recruiting
- NCT07424326 — Extended Ablation Versus Pulmonary Vein Isolation to Treat Persistent Atrial Fibrillation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05004220 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Charles University, Czech Republic
- Last refreshed: 6 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05004220.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing